Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for The Readout newsletter to get the latest on biotech delivered to your inbox. And subscribe to STAT+ to access daily, market-moving coverage of the biotech sector — from startup funding to clinical trial readouts

Biotech Isabella Cueto

Faster drug approval route sparks investment in rare kidney disease treatments

Drug companies, regulators, and researchers are collaborating to develop new treatments for rare kidney diseases.

Read The Story

Biotech Kate Sheridan

OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking

Biotech Damian Garde

FDA approves Axsome’s fast-acting treatment for major depression

Biotech Adam Feuerstein

Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder

Biotech Angus Chen

Virtual Event – Biomarkers: The Foundation of Personalized Oncology

All Coverage

Biotech Ryan Cross — The Boston Globe

‘We’re finally here’: Harvard graduate spearheads custom gene therapy for younger brother

Biotech Matthew Herper

Blueprint Medicines drug reduces mastocytosis symptoms in a new study, meeting investor expectations

Exclusive Allison DeAngelis

Ex-Google CEO’s VC firm brings in hype-busting researcher to expand its biotech investments

Biotech Jason Mast

Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup

Biotech Adam Feuerstein

Brainstorm to seek FDA approval for ALS stem-cell treatment, despite agency objections

Biotech Catherine Carlock and Jonathan Saltzman — the Boston Globe

Amid Aduhelm woes, Biogen moves to pare back office space

Biotech Damian Garde and Adam Feuerstein

Everything you need to know before the next big Alzheimer’s readout

Adam's Take Adam Feuerstein

With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally

Biotech Adam Feuerstein

Karuna Therapeutics’ schizophrenia drug achieves study goals, heralding new treatment approach

Biotech Adam Feuerstein

Serious liver side effects detour Amgen’s effort to expand use of its KRAS-blocking lung cancer drug

Biotech Adam Feuerstein

Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder

Biotech Damian Garde

Alnylam therapy for increasingly common heart disease succeeds in closely watched trial

Biotech Allison DeAngelis

Alexis Borisy, biotech’s ‘man of many hats,’ dons another

Biotech Scott Kirsner — Boston Globe

This billionaire has quietly driven Boston’s biotech industry for decades

Biotech Adam Feuerstein

Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophy

Biotech Jason Mast

Drug companies could create new drugs to protect the Covid vulnerable. Why aren’t they?

Health Jonathan Wosen

Genomics is racing toward a $100 genome. Are we ready for it?

Biotech Adam Feuerstein

FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results

Biotech Allison DeAngelis

American Cancer Society’s VC arm partners with Third Rock on oncology companies

Health Jason Mast

As new variant spreads, a crucial drug to protect the most vulnerable goes vastly underused

Biotech Jonathan Wosen

This biotech is betting dietary changes can reshape cancer care. Even if it works, can Faeth make a profit?

Biotech Matthew Herper

New data might have led to a different result for Amarin fish oil drug, FDA panelists say

Biotech Adam Feuerstein

Biotech executives pull in some of health care’s biggest paydays, with Regeneron’s CEO sitting atop the pack

Business Bob Herman

Biotech

Faster drug approval route sparks investment in rare kidney disease treatments

OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking

FDA approves Axsome’s fast-acting treatment for major depression

Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder

Virtual Event – Biomarkers: The Foundation of Personalized Oncology

All Coverage

‘We’re finally here’: Harvard graduate spearheads custom gene therapy for younger brother

Blueprint Medicines drug reduces mastocytosis symptoms in a new study, meeting investor expectations

Ex-Google CEO’s VC firm brings in hype-busting researcher to expand its biotech investments

Merck, a loser in the Covid vaccine race, reinvests in mRNA through a Cambridge startup

Brainstorm to seek FDA approval for ALS stem-cell treatment, despite agency objections

Amid Aduhelm woes, Biogen moves to pare back office space

Everything you need to know before the next big Alzheimer’s readout

With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally

Karuna Therapeutics’ schizophrenia drug achieves study goals, heralding new treatment approach

Serious liver side effects detour Amgen’s effort to expand use of its KRAS-blocking lung cancer drug

Amgen to acquire ChemoCentryx for $4 billion, adding newly approved drug for autoimmune disorder

Alnylam therapy for increasingly common heart disease succeeds in closely watched trial

Alexis Borisy, biotech’s ‘man of many hats,’ dons another

This billionaire has quietly driven Boston’s biotech industry for decades

Sarepta to seek early FDA approval for gene therapy to treat Duchenne muscular dystrophy

Drug companies could create new drugs to protect the Covid vulnerable. Why aren’t they?

Genomics is racing toward a $100 genome. Are we ready for it?

FDA agrees to review ALS treatment from Biogen, despite inconclusive clinical trial results

American Cancer Society’s VC arm partners with Third Rock on oncology companies

As new variant spreads, a crucial drug to protect the most vulnerable goes vastly underused

This biotech is betting dietary changes can reshape cancer care. Even if it works, can Faeth make a profit?

New data might have led to a different result for Amarin fish oil drug, FDA panelists say

Biotech executives pull in some of health care’s biggest paydays, with Regeneron’s CEO sitting atop the pack

Biotech employees cash in health care’s largest salaries, while people working at providers sit near the bottom

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day